Quoin pharmaceuticals receives nasdaq deficiency notice regarding minimum bid price requirement

Ashburn, va., june 15, 2022 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that the company received a written notification (the "notification letter") from the nasdaq stock market llc ("nasdaq") on june 10, 2022, notifying the company that it is not in compliance with the minimum bid price requirement set forth in nasdaq rules for continued listing on nasdaq.
QNRX Ratings Summary
QNRX Quant Ranking